Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its Series C2 financing round. The round saw participation from the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund, managed by China Grand Prosperity Investment, Haibang Venture, and Howbuy Primary Fund, with existing shareholders New Alliance Capital and Lilly Asia Ventures (LAV) also increasing their investment. Following the Series C1 financing in May, this new funding brings the total amount raised in the C-round to RMB 322 million (USD 44.8 million).
Company Background and Pipeline Development
Founded in 2018, Lynk Pharmaceuticals is at the forefront of research and development for First-in-Class (FIC) and Best-in-Class (BIC) drugs targeting autoimmune diseases, inflammation, and oncology. In recent months, the company has achieved significant milestones with the release of Phase II clinical trial data for LNK01001 in rheumatoid arthritis, atopic dermatitis, and ankylosing spondylitis, all showing substantial therapeutic effects and a high safety profile. These results underscore the benefits of small molecule JAK1 inhibitors, known for their rapid onset and superior efficacy.
Clinical Progress and Future Plans
Lynk Pharmaceuticals has submitted applications for an End of Phase II (EOP2)/Pre-Phase III meeting, with several indications set to enter Phase III clinical trials. The company aims to expedite the process to benefit more patients. Additionally, the first patient dosing in a Phase 1b trial of LNK01004 for psoriasis and atopic dermatitis was achieved in the first half of this year. Early clinical trial data from LNK01002 and LNK01003 are also showing promise, while the company’s pre-clinical pipeline continues to advance steadily.-Fineline Info & Tech
